Galectin Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
08/08/2025 17:05
Galectin Therapeutics Inc GALT.OQ GALT.O is expected to show no change in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025 LSEG's mean analyst estimate for Galectin Therapeutics Inc is for a loss of 16 cents per share. The one available analyst rating on the shares is "buy". The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Galectin Therapeutics Inc is $6.00, about 36% above its last closing price of $3.84 This summary was machine generated August 8 at 16:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study